Gsa Capital Partners LLP Savara Inc Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Savara Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 708,463 shares of SVRA stock, worth $1.83 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
708,463
Previous 87,705
707.78%
Holding current value
$1.83 Million
Previous $243,000
564.61%
% of portfolio
0.11%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding SVRA
# of Institutions
135Shares Held
163MCall Options Held
54.8KPut Options Held
4.1K-
Nea Management Company, LLC Timonium, MD24.5MShares$63.1 Million6.43% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$45.4 Million16.36% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$31.9 Million8.25% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$29.6 Million2.0% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$28.4 Million2.18% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $294M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.